Select stem cells derived human umbilical cord blood are considered to be universal donor cells because they are not immediately recognized as foreign to the immune system. These cells home to damaged tissue and are known to secrete molecules called trophic factors.
Trophic factors from mesenchymal stem cells are known to stimulate repair of damaged nervous tissue in both the brain and the spinal cord. Some of these are neurotrophic factors that promote neuronal growth, induce new blood vessel growth, neurogenesis and astroglial activation, encourage synaptic connection and axonal remyelination, decrease programed cell death, and regulate microglial activation.
Mesenchymal stem cells stimulate brain repair after stroke1 and traumatic brain injury.
Animal studies show that mesenchymal stem cell can migrate into the brain and survive.
Because we utilize cord tissue-derived mesenchymal stem cells, we are able to offer treatment to any qualified patient, even patients who have saved their own cord blood at birth. We will discuss several additional advantages of allogeneic cord-derived stem cells below.
There is evidence to support that bone marrow-derived mononuclear cells are safe and improve the quality of life in children with neurological disorders including cerebral palsy.
Our stem cells come from human umbilical cord tissue (allogeneic mesenchymal). Umbilical cords are donated by mothers after a healthy birth. All umbilical cord-derived stem cells are screened for viruses and bacteria to International Blood Bank Standards.
Umbilical cord-derived stem cells allow our physicians to administer uniform doses and they do not require any stem cell collection from the patient, which, especially for children and their parents, can be an arduous process. Because they are collected right after (normal) birth, umbilical cord-derived cells are much more potent than their "older" counterparts like fat-derived cells for instance. Cord tissue-derived mesenchymal stem cells pose no rejection risk because the body does not recognize them as foreign.
Our laboratory undertakes a very disciplined screening process to identify cells know to have the best anti-inflammatory activity, the best immune modulating capacity, and the best ability to stimulate regeneration."
Cord blood mesenchymal stem cells (MSCs) that were isolated and grown in our global laboratories to create master cell banks are identical to cells currently used in the United States under US FDA regulation.
These cells serve as the starting material for cellular products used in MSC clinical trials for two Duchenne's muscular dystrophy patients under US FDA's designation of Investigational New Drug (IND) for single patient compassionate use. (IND 16026 DMD Single Patient).
The body's immune system is unable to recognize cord blood stem cells as foreign and therefore not rejected. Cord blood stem cells have been administered thousands of times at ProGenaCell approved clinics and never been a single rejection (graft vs. host disease). As a matter of fact, allogeneic (not the patient's own) mesenchymal stem cells are approved to treat graft vs. host disease in Canada and New Zealand.
Cord blood stem cells also proliferate/differentiate more efficiently than "older" cells, such as those found in the fat and therefore, they are considered to be more "potent".
In this next video (just past the 1 minute mark), Arnold Caplan, PhD explains the mechanism by which donor mesenchymal stem cells shield themselves from the recipient's immune system. Dr. Caplan is the scientist who discovered the mesenchymal stem cell. He is commonly referred to as "the father of the mesenchymal stem cell".
The umbilical cord-derived stem cells are administered via intrathecal injection by licensed physicians.
Treatment protocol will be assigned by staff physicians after the patient has submitted all requested medical information and received approval. A patient's recommended protocol may differ from the example given below.
Proper follow-up is an essential part of the cerebral palsy treatment process. Our primary goal is to ensure that your child is progressing safely. Regular follow-up also enables us to evaluate efficacy and improve our CP treatment protocols based on observed outcomes.
Therefore, our medical staff will be contacting you after 1 month, 3 months, 6 months, and 1 year to monitor your child's progress.
Fill out an Information Request Form Today! How can we help?